B. Abstract Format
The title should clearly define the topic and contain no abbreviations.
There is a character limit of 200 characters including spaces.
Enter the title as you were writing a sentence, only CAPITALIZE the first letter of the sentence and proper nouns, nothing else.
Do not use punctuation at the end of the sentence UNLESS it is a question mark (?) or exclamation point (!)
No symbols are permitted; write out the name of the symbol (i.e. beta, alpha, etc.).
You will be allowed to use symbols for the abstract body.
The size of the abstract is limited to 2000 characters including spaces (or approx. 400 words). This includes body of abstract only.
The body must contain four separate paragraphs: a) Introduction; b) Methods; c) Results; and d) Conclusions. The abstract should be informative and detailed.
Standard abbreviations may be used as follows: on first use, spell out the full term and follow with abbreviation in parentheses. Abbreviations can be used subsequently.
Use generic names of drugs.
It is NOT acceptable to state that “The results will be discussed.” Inclusion of specific data is necessary for reviewers.
Indicate the major new findings of the study.
References are not required.
Study Groups/Acknowledgements: These will be noted above your abstract in the CUAJ.
To insert a figure (image or graph) please upload the files as a JPG in the “Figures” step. JPGs must be at least 300 DPI and measure at least 3.5 inches wide.
Tables must be created in MS Word (not images pasted into Word) and can also be uploaded in the “Figures” step.
All tables/figures must be titled and all images/figures must have a caption.
A reference to accompanying tables/figures must be made within the body of the abstract (i.e., Patient demographics are listed in Table 1).
Take care to list ALL authors in the relevant section of the submission site. Spell out
completely the names of all authors using full first and last names.
Middle name initials are to be placed in the special field for this. It should be a capital
letter with a period at the end (i.e., Stephanie M. Smith).
Maintain consistency in author names on multiple abstracts to avoid duplication in the
Affiliations (department, institution) should be spelled out in full.
If the author(s) of the abstract is an employee(s) of, or has a financial
relationship with the commercial interest that controls the content of the presentation, he/
she cannot be the presenting author. However, investigators responsible for research and
development are permitted to present as long as they resolve their Conflict of Interest (COI) and
as long as they are not employees of the commercial interest. In all printed publications, the
presenting author will be underlined.
Conflict of Interest and Disclosure Statement:
This is required for the submitting author and the
presenting author. It is the responsibility of the submitting author to collect this information.
Topic List: Authors must select an abstract topic (only one) from the provided list.
Benign Prostatic Hyperplasia
Endourology - Laparoscopy/Robotics
Endourology - Nephrolithiasis
Equity, Diversity, Inclusion and Racism in Urology/Medicine
Improving Patient Relations/Practice Management/Communications/Physician Wellness and Burnout
Lower Urinary Tract Reconstruction and Genitourinary Trauma
Male/Female Pelvic Pain
Oncology - Bladder
Oncology - General
Oncology - Kidney/Ureter
Oncology - Penis/Testis/Urethra
Oncology - Prostate
Sexual Dysfunction and Infertility
Technical Advances in Urology
Training and Evaluation
Urinary Incontinence and Voiding Dysfunction
Urological Infections (Includes STDs)